New ways to image and target tumour hypoxia and its molecular responses. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Dubois, Ludwig J.; Niemans, Raymon; van Kuijk, Simon J.A.; Panth, Kranthi M.; Parvathaneni, Nanda-Kumar; Peeters, Sarah G.J.A.; Zegers, Catharina M.L.; Rekers, Nicolle H.; van Gisbergen, Marike W.; Biemans, Rianne; Lieuwes, Natasja G.; Spiegelberg, Linda; Yaromina, Ala; Winum, Jean-Yves; Vooijs, Marc; Lambin, Philippe
• Is Part Of: Radiotherapy and oncology. Volume 116:Issue 3(2015:Sep.)
• Page Start: 352
• Page End: 357
• Publication Date: 2015-09
• Subjects: Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2015.08.022
• Languages: English
• ISSNs: 0167-8140

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st005">Abstract</title> <sec> <p id="sp0005">Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. Detection of hypoxia, preferably in a non-invasive manner, could therefore predict treatment outcome and serve as a tool to individualize treatment. This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hypoxia (hypoxia-activated prodrugs) or hypoxia response (carbonic anhydrase IX inhibitors) is summarized. Last, window-of-opportunity trials implementing non-invasive imaging are proposed as an important tool to prove anti-tumour efficacy of experimental drugs early during drug development.</p> </sec> </abstract>